Cochrane Abstracts
Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Long‐acting Beta2‐agonists Versus Theophylline for Maintenance Treatment of Asthma." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437957/all/Long‐acting_beta2‐agonists_versus_theophylline_for_maintenance_treatment_of_asthma.
Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437957/all/Long‐acting_beta2‐agonists_versus_theophylline_for_maintenance_treatment_of_asthma. Accessed March 15, 2025.
Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437957/all/Long‐acting_beta2‐agonists_versus_theophylline_for_maintenance_treatment_of_asthma
Long‐acting Beta2‐agonists Versus Theophylline for Maintenance Treatment of Asthma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437957/all/Long‐acting_beta2‐agonists_versus_theophylline_for_maintenance_treatment_of_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma
ID - 437957
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437957/all/Long‐acting_beta2‐agonists_versus_theophylline_for_maintenance_treatment_of_asthma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
